1y return+24.9%S&P 500 +20.9%
3y return+37.4%S&P 500 +68.5%
5y return+33.5%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2016: $300 against $334 in the S&P 500.2
Rhenman & Partners Asset Management ABS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| UNHUnited Health Group Inc | $38.9M | 3.7% | +105.7% |
| CVSCvs Health Corp | $28.9M | 2.7% | −17.0% |
| Astrazeneca PLCCUSIP G0593M107 | $28.5M | 2.7% | New |
| MRKMerck & Co Inc | $27.4M | 2.6% | New |
| LLYLilly Eli & Co | $26.8M | 2.5% | −33.8% |
| ABBVAbbvie Inc | $24.4M | 2.3% | +35.2% |
| ALHCAlignment Healthcare Inc | $23.7M | 2.2% | −5.4% |
| EWEdwards Lifesciences Corp | $23.5M | 2.2% | +59.5% |
| GILDGilead Sciences Inc | $22.5M | 2.1% | +6.3% |
| Jazz Pharmaceuticals PLCCUSIP G50871105 | $21.1M | 2.0% | +15.2% |
| BIIBBiogen Inc | $20.5M | 1.9% | −13.1% |
| SYKStryker Corporation | $20.5M | 1.9% | +36.0% |
| BSXBoston Scientific Corp | $19.2M | 1.8% | −27.9% |
| JNJJohnson & Johnson | $18.4M | 1.7% | New |
| GHGuardant Health Inc | $17.3M | 1.6% | −20.7% |
| REGNRegeneron Pharmaceuticals | $17.1M | 1.6% | −43.1% |
| GKOSGlaukos Corp | $16.6M | 1.6% | +41.7% |
| BMRNBiomarin Pharmaceutical Inc | $16.6M | 1.6% | +40.3% |
| NRIXNurix Therapeutics Inc | $16.6M | 1.6% | +118.3% |
| NTRANatera Inc | $16.6M | 1.6% | +18.3% |
| MIRMMirum Pharmaceuticals Inc | $16.3M | 1.5% | +50.3% |
| INSMInsmed Inc | $16.2M | 1.5% | −4.9% |
| THCTenet Healthcare Corp | $15.9M | 1.5% | +57.8% |
| TMOThermo Fisher Scientific Inc | $15.8M | 1.5% | −23.6% |
| CNCCentene Corp Del | $15.7M | 1.5% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| NTRANatera Inc | September 30, 2022 | +519.5% | $16.6M |
| MIRMMirum Pharmaceuticals Inc | March 31, 2024 | +366.0% | $16.3M |
| AXSMAxsome Therapeutics Inc. | March 31, 2023 | +296.8% | $15.4M |
| MCKMckesson Corp | March 31, 2021 | +287.4% | $12.5M |
| GKOSGlaukos Corp | June 30, 2020 | +263.8% | $16.6M |
| THCTenet Healthcare Corp | June 30, 2021 | +179.3% | $15.9M |
| AVRAnteris Technologies Global | March 31, 2025 | +170.6% | $15.2M |
| ABBVAbbvie Inc | June 30, 2020 | +156.3% | $24.4M |
| LLYLilly Eli & Co | June 30, 2023 | +155.8% | $26.8M |
| GHGuardant Health Inc | September 30, 2025 | +140.1% | $17.3M |
Sold off last quarter
- ADPTAdaptive Biotechnologies Cor was $10.0M
- IQVIqvia Hldgs Inc was $9.0M
- Nuvalent IncCUSIP 670703107 was $8.3M
- Apogee Therapeutics IncCUSIP 03770N101 was $6.3M
- Ascendis Pharma A/sCUSIP 04351P101 was $3.4M
- Esperion Therapeutics Inc NeCUSIP 29664W105 was $2.7M
- IMCRImmunocore Hldgs PLC was $2.6M
- CMPXCompass Therapeutics Inc was $609K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +11.9% | +14.8% |
| March 31, 2026 | −6.5% | −4.6% |
| December 31, 2025 | +15.3% | +2.4% |
| September 30, 2025 | +3.6% | +7.8% |
| June 30, 2025 | −1.5% | +10.5% |
| March 31, 2025 | +1.2% | −4.6% |
| December 31, 2024 | −10.1% | +2.1% |
| September 30, 2024 | +8.2% | +5.4% |
| June 30, 2024 | −2.2% | +4.0% |
| March 31, 2024 | +10.0% | +10.0% |
| December 31, 2023 | +13.0% | +11.2% |
| September 30, 2023 | −6.6% | −3.6% |
| June 30, 2023 | +4.2% | +8.3% |
| March 31, 2023 | −1.6% | +7.0% |
| December 31, 2022 | +7.1% | +7.1% |
| September 30, 2022 | +1.4% | −5.3% |
| June 30, 2022 | −9.1% | −16.5% |
| March 31, 2022 | −3.3% | −4.9% |
| December 31, 2021 | +3.6% | +10.7% |
| September 30, 2021 | −4.2% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Rhenman & Partners Asset Management AB Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1599882&type=13F-HR&dateb=&owner=include&count=40CIK 1599882
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1599882/000121390026088652/Filed August 13, 2026 · accession 0001213900-26-088652